Building Resilient Pharmaceutical Facilities: Strategic Insights for a Rapidly Evolving Industry

This expansion is not just about scaling production—it’s about rethinking how facilities are built, operated, and maintained. From new construction to major upgrades, pharmaceutical companies are racing to increase capacity, accelerate timelines and bring life-saving solutions to market faster. But with these ambitions come new challenges: tighter regulations, labor shortages and the need for smarter, more agile construction strategies.

The Reshoring Movement and Its Implications

One of the most significant trends impacting the industry is the reshoring of pharmaceutical manufacturing. Companies are moving production back to the United States to gain greater control over supply chains, reduce geopolitical risk, and respond more quickly to domestic demand. This shift offers tremendous opportunity but also introduces additional complexity.

Reshoring requires navigating tight labor markets, rising material costs and heightened competition for skilled trades. It also demands an increased level of coordination among stakeholders, from architects and engineers to general contractors and facility managers. Success depends on building smarter, faster and more efficiently, without compromising safety, compliance or long-term performance.

Balancing Global Reach with Local Agility

While domestic investment is surging, global partnerships remain essential, pharmaceutical manufacturers must maintain the flexibility to pivot internationally when needed, whether to source raw materials, collaborate on research or distribute products. This dual focus—local resilience and global agility—requires facilities that are adaptable, scalable, and built to withstand change.

In this context, construction planning becomes a strategic imperative. Decisions made during design and preconstruction phases can determine a facility’s ability to meet evolving regulations and avoid costly delays by maintaining uninterrupted production. Every element, from layout and materials to coatings and finishes, must be selected with long-term performance in mind.

The Role of Coatings in Pharmaceutical Construction

Among the many components of a pharmaceutical facility, coatings are often underestimated. Yet they play a critical role in ensuring sterility, durability and regulatory compliance. In environments where contamination control is paramount, coatings are not just cosmetic—they’re functional elements of the infrastructure.

Why Coatings Matter

Pharmaceutical facilities are subject to rigorous cleaning protocols, frequent chemical exposure, and continuous operation. Coatings must:

• Resist microbial growth and support sterilization procedures
• Create smooth, seamless surfaces that prevent contamination
• Withstand harsh chemicals, abrasion and thermal cycling
• Comply with US Food and Drug Administration (US FDA) and cGMP standards, supporting inspections and certifications

When coatings fail—whether due to improper selection, poor application or environmental stress—the consequences can be severe. Rework, shutdowns, and compliance violations can derail production and damage reputations.

Strategic Coating Selection

Choosing the right coating system is not a one-size-fits-all decision. Different areas of a facility have different requirements. Cleanrooms, for example, demand seamless, non-porous finishes that can withstand repeated disinfection. Production floors may require high-impact resistance and chemical durability. Secondary containment areas must be able to handle spills and prevent environmental release.

Early collaboration with coatings experts helps identify the best solutions for each space. It also ensures proper sequencing, surface preparation and environmental controls during installation—factors that are critical to long-term performance.

Accelerating Timelines Without Sacrificing Quality

Speed is a necessary feature of today’s pharmaceutical construction projects. Companies are under pressure to bring facilities online quickly to meet market demand. However, rushing construction can lead to errors, delays and compromised quality.

An industry report from Sherwin-Williams and Endeavor Business Media found that nine in 10 construction professionals experience costly project delays. Among those working on pharmaceutical projects, 63 percent cited meeting timelines as their biggest challenge.

To stay on track, stakeholders must look for every advantage. Coatings can contribute to faster schedules through:

• Fast-cure technologies that reduce downtime between trades
• Shop-applied fireproofing that enhances safety and streamlines field installation
• Pre-approved systems that simplify compliance and reduce inspection delays

These benefits are only realized when coatings are integrated into the construction plan from the outset, not treated as a last-minute finish.

Minimizing Downtime and Maximizing Performance

Once operational, pharmaceutical facilities must maintain peak performance with minimal interruptions. Coatings contribute to this goal by:

• Reducing maintenance needs through long-lasting durability
• Supporting sterility with cleanable, non-shedding surfaces
• Protecting infrastructure from corrosion, impact and chemical exposure

Facilities built strategically with high-performance coatings experience fewer shutdowns, lower lifecycle costs and greater operational resilience. This is especially important in high-throughput environments where downtime can translate to millions in lost revenue.

Compliance and Sustainability

Regulatory compliance is non-negotiable in pharmaceutical manufacturing. Coatings must meet US FDA, cGMP, and other standards to ensure product safety and facility integrity. But increasingly, sustainability is also a key consideration.

Facility owners are seeking coatings that:

• Support LEED certification and other green building standards
• Eliminate red list chemicals and reduce environmental impact
• Offer low-VOC formulations that improve indoor air quality

Balancing compliance and sustainability requires careful material selection and documentation. It also demands transparency from suppliers and coordination among design teams.

Navigating Workforce Constraints

As pharmaceutical construction accelerates, labor shortage is becoming a critical constraint. Skilled tradespeople, especially those experienced in cleanroom and sterile environment construction, are in high demand. According to Associated Builders and Contractors, the construction industry must attract 349,000 new workers in 2026, with demand expected to increase again to 456,000 workers in 2027. This highlights the continued strain on the industry’s labor pipeline, which is further complicated by an aging workforce, with many professionals nearing retirement age. This shortage can lead to bottlenecks, quality issues and increased costs if not addressed early in the planning process.

To mitigate these risks, facility owners and contractors are increasingly turning to prefabrication and modular construction techniques. These approaches allow for controlled application environments, reduce on-site labor needs and shorten project timelines. Prefabricated wall panels, modular cleanroom systems and pre-coated structural components help teams maintain quality while navigating workforce limitations.

By embracing modular strategies, stakeholders can build smarter and more resilient facilities—ones that are not only faster to construct but also easier to maintain and adapt over time.

Three Strategies to Stay Ahead

To navigate the complexities of modern pharmaceutical construction, facility owners and contractors can adopt the following strategies:

1. Engage Early and Collaborate Often

Early engagement with coatings experts, architects and construction teams is essential to aligning expectations and avoiding costly surprises. When coatings are considered during the design and preconstruction phases, not just at the end, they can be integrated more effectively into the overall construction timeline.

This collaboration should include discussions around substrate preparation, environmental conditions, cure times and inspection protocols. For example, in cleanroom environments, coatings may require specific humidity and temperature controls during application. Coordinating these requirements with HVAC and scheduling teams ensures that installation proceeds smoothly and meets performance standards.

Moreover, early collaboration fosters better communication across trades. When coatings contractors are looped in from the start, they can help identify potential conflicts with other systems and propose solutions that maintain compliance and performance.

2. Focus on Durability and Lifecycle Value

Durability is not just about withstanding wear and tear—it’s about ensuring long-term performance under the unique stresses of pharmaceutical operations. Coatings must endure frequent cleaning with aggressive disinfectants, exposure to corrosive chemicals and constant foot and equipment traffic.

Selecting systems with proven resistance to abrasion, impact and chemical degradation reduces the frequency of repairs and minimizes operational disruptions. Seamless flooring systems, for instance, eliminate joints and cracks where contaminants can accumulate, supporting sterility and simplifying maintenance.

Lifecycle value also includes ease of repair and recoats. Facilities that can be updated without full shutdowns or extensive demolition are more adaptable to future needs. Coatings that allow for spot repairs or phased upgrades help maintain uptime and reduce long-term cost of ownership.

Additionally, investing in high-performance coatings upfront can reduce the need for replacement during regulatory audits or facility expansions. This foresight supports business continuity and protects capital investments.

3. Integrate Compliance and Sustainability

Today’s pharmaceutical facilities must meet both strict regulatory compliance and growing sustainability expectations. Coatings play a pivotal role in achieving both.

From a compliance standpoint, coatings must meet US FDA and cGMP standards, which often require documentation of material composition, installation procedures and performance characteristics. Working with suppliers who provide clear technical data sheets, third-party certifications and validation support simplifies the approval process and reduces risk during inspections.

On the sustainability front, coatings that contribute to LEED certification or other green building standards are increasingly preferred. Low-VOC formulations, systems free of red list chemicals and products manufactured with environmentally responsible processes help reduce the facility’s environmental footprint.

Sustainability also intersects with durability. Long-lasting coatings reduce waste and resource consumption over time. Facilities that prioritize both compliance and sustainability are better positioned to meet stakeholder expectations, attract talent and align with broader corporate responsibility goals.

Looking Ahead: Building for What’s Next

The pharmaceutical industry is not just growing, it’s evolving. Advanced therapies, personalized medicine and digital manufacturing are reshaping how drugs are developed and delivered. Facilities must be built to accommodate these changes, with infrastructure that supports innovation and adapts to new technologies.

Construction teams must think beyond the immediate project. They must anticipate future needs, regulatory shifts and operational challenges. Coatings, while just one piece of the puzzle, are a powerful tool in building facilities that are safe, compliant and ready for what’s next.

Conclusion

Pharmaceutical construction is a high-stakes endeavor. Every decision, from site selection to surface finishes, affects the facility’s ability to deliver life-saving medications and solutions efficiently and safely. Coatings play a vital role in this equation, contributing to sterility, durability, compliance and speed.

By treating coatings as strategic infrastructure and integrating them into the construction process early, stakeholders can build facilities that meet today’s demands and tomorrow’s possibilities. In a rapidly changing industry, this proactive approach is not just smart—it’s essential.

About the Author

Allan Haynes is the Pharmaceutical Key Account Manager for North America at Sherwin-Williams Protective and Marine Division. With 26 years of experience at Sherwin-Williams, Haynes has developed extensive expertise in the industry. He is a certified AMPP Coatings Inspector and holds a bachelor's degree from the University of South Carolina.